Reata Pharmaceuticals, Inc. Announces Closing of Initial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Reata Pharmaceuticals, Inc. Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares of Class A Common Stock

IRVING, Texas, June 01, 2016 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (“Reata”), a clinical-stage biopharmaceutical company, today announced the completion of its initial public offering of 6,325,000 shares of its Class A common stock at $11.00 per share, which includes the exercise in full by the underwriters of their over-allotment option. The shares of Class A common stock began trading on The NASDAQ Global Market on May 26, 2016, under the ticker symbol “RETA.”

The net proceeds received by Reata from the offering (after deducting underwriting discounts and commissions and estimated offering expenses) were approximately $60.9 million. Reata intends to use the net proceeds from the offering to advance the development of its lead product candidate, bardoxolone methyl, through a Phase 3 trial and additional Phase 2 programs, to advance the development of its product candidate omaveloxolone through Phase 2 clinical trials, and to provide funds for working capital and other general purposes, including preclinical studies and clinical trials.

Citigroup, Cowen and Company and Piper Jaffray & Co. acted as joint book-running managers for the offering.

A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission (the “SEC”). This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering is being made only by means of a written prospectus. A copy of the final prospectus relating to these securities may be obtained for free from:

Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (800) 831-9146;

Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, telephone: (631) 274-2806, or fax (631) 254-7140; or

Piper Jaffray & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Email: prospectus@pjc.com, or telephone at (800) 747-3924

About Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a variety of serious or life-threatening diseases. Reata focuses on drugs with novel mechanisms of action that modulate important regulatory proteins, called transcription factors, that coordinate the cellular response to stressors by activating or suppressing the activity of many target proteins.

Forward-Looking Statements

This press release includes certain disclosures which contain “forward-looking statements,” including, without limitation, statements regarding the anticipated timing of completion of the offering, and the anticipated use of proceeds of the offering. You can identify forward-looking statements because they contain words such as “believes” and “expects.” Forward-looking statements are based on Reata’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Reata’s filings with the SEC, including its registration statement on Form S-1, as amended from time to time, under the caption “Risk Factors.”

Contact: Reata Pharmaceuticals, Inc. (972) 865-2219 info@reatapharma.com http://news.reatapharma.com

Investor Relations: The Trout Group Lee M. Stern, CFA (646) 378-2922 IR@reatapharma.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LKQ’s Europe ERP Mess Turns Into a Credibility Test

Updated Category News Views 115

A software rollout should not be able to punch a company in the teeth twice, yet LKQ shareholders have watched precisely that ugly movie in 2026. The October 23 disclosure was a real gut-check: an immediate CEO departure, a $16 million net loss, and renewed acknowledgement that the German enterprise-resource-planning rollout was disrupting Europe. Shares fell $5.05, or...

Continue Reading
Caregiver Strategy Puts a Hard Truth on the Table Today

Updated Category News Views 57

Sixty-three million people carrying care responsibilities is not a side issue; it is a national load-bearing wall. The 2026 National Strategy to Support Family Caregivers arrives with that reality plainly in view, and frankly, it is overdue for the country to treat family care as core infrastructure rather than a private household problem somebody is expected to absorb...

Continue Reading
Mindstream’s Jordan AI Campus Faces Its First Real Test

Updated Category News Views 65

Jordan’s AI ambitions just got attached to a very large gas meter. Mindstream Energy has unveiled a plan for an AI-ready data-center campus at Al-Risha in Mafraq Governorate, built around dedicated natural-gas generation rather than a conventional dependence on the utility grid. The headline number is 400 megawatts of eventual capacity. The number that matters first is...

Continue Reading
DHC’s Ulta Rollout Gets a Useful Pricing Correction

Updated Category News Views 49

A face-wash price tag just became the most revealing part of DHC’s Ulta expansion. The company corrected an earlier announcement that had listed its new Deep Cleansing Face Wash at $31.50; the actual price is $19.00. That may sound like tiny housekeeping, and in the grand scheme it is, but consumer brands live or die on this kind of detail. A cleanser priced near $20...

Continue Reading
Zoomcar's November 23 Report Puts Execution on Trial

Updated Category News Views 130

A Date on the Board, Not a Verdict November 23 is when Zoomcar finally has to put some fresh numbers beside the story. The Bengaluru-based peer-to-peer car-sharing marketplace says it will release second-quarter fiscal 2027 financial and operating results that Monday, covering the quarter ended September 30, 2026. Management also plans a live webcast at 8:00 a.m. Eastern...

Continue Reading
MemorialCare Adds AI Guardrails for Hidden Aneurysms

Updated Category News Views 141

A brain scan ordered for one reason can suddenly expose a risk nobody knew was sitting there. That is the sober promise behind MemorialCare Neuroscience Institute's rollout of Rapid Aneurysm, an artificial-intelligence tool embedded in qualifying CTA and MRA brain scans across its inpatient and outpatient network. MemorialCare says it is the first health system in Los...

Continue Reading
Alphabet Lawsuit Puts Gemini Delays Under a Microscope

Updated Category News Views 173

July’s twin punches to Alphabet shares were not the sort of wobble investors can casually shrug off. First came a report on July 16 that Google was months behind on Gemini 3.5 Pro, its flagship AI model, after disappointing results from updated training data. Then came the harder financial reality a week later: a much larger 2026 capital-spending plan, negative...

Continue Reading
First Grade Literacy Push Deserves a Harder Look Now

Updated Category News Views 146

A reading gap can become a concrete wall before anyone bothers measuring it. That is the uncomfortable point behind Ignite Reading's First Grade Promise, and it deserves more attention than another polished education announcement usually gets. At a Nov. 5 Convene 2026 gathering in Boston, 56 district and literacy leaders from six states focused on getting children reading...

Continue Reading
Korla Kiln Gains Show How Cement Efficiency Is Won

Updated Category News Views 12

A cement kiln does not care about corporate slogans; it cares whether the flame holds, the bearings stay alive, and the feed keeps moving. That is why the work at Xinjiang Tianshan Cement's Tashidian branch in Korla deserves a closer look. This is not a glossy tale about a futuristic factory appearing overnight. It is an account of an old, unforgiving industrial process...

Continue Reading
SM's PHP70 Billion Profit Shows a Balanced Growth Engine

Updated Category News Views 0

PHP70.2 billion in nine-month profit is not the sort of number that needs a brass band; it needs a closer look at the machinery underneath. SM Investments grew consolidated net income 9% from PHP64.4 billion a year earlier, while revenue rose a more modest 5% to PHP506.8 billion. That spread is encouraging, but it also tells investors not to lazily call this a one-speed...

Continue Reading

Top 5 Most Recently Viewed Articles

Rob Shields Steps Up as Chief Growth Officer at Greenlane

Updated Category News Views 533

Greenlane Welcomes Rob Shields as Chief Growth Officer Greenlane Holdings, Inc. (NASDAQ: GNLN), a distributor of premium cannabis accessories and vaporization products, has recently appointed Rob Shields as Chief Growth Officer. This transition comes at a pivotal time for the company, as it aims to enhance its market presence and address ongoing challenges in the...

Continue Reading
HealthBird Revolutionizes Healthcare in Ecuador with Collaboration

Updated Category News Views 436

HealthBird Partners with Ecuador to Innovate Healthcare HealthBird, a leading health technology provider, is making waves as it spearheads an innovative healthcare initiative in Ecuador. The company, associated with OneNest, aims to support the nation in transforming its healthcare system into a modern, efficient, and sustainable framework. With a commitment to investing...

Continue Reading
Exciting New Travelzoo Offers for Enthusiasts Awaiting You

Updated Category News Views 579

Exciting Travel Offers for Members Travelzoo® (NASDAQ: TZOO), a renowned name for travel enthusiasts, has recently unveiled new Club Offers designed specifically for its members. These unique deals have been meticulously vetted and negotiated to ensure travelers can enjoy exceptional experiences at remarkable prices. Explore Enchanting Destinations Among the latest...

Continue Reading
Join Tiptree for Insights on Q3 2024 Performance

Updated Category News Views 180

Join Tiptree for Insights on Q3 2024 Performance Tiptree Inc. (NASDAQ:TIPT) is gearing up for an engaging conference call and live webcast to delve into the details of its Q3 2024 results. Scheduled for Thursday, October 31, 2024, at 10:30 AM ET, this event promises to be an informative session for all stakeholders. How to Access the Conference Call Participants wishing...

Continue Reading
WOW! Expands Services in Florida with New Fiber Customers

Updated Category News Views 236

WOW! Expands Its Fiber Network in Florida Residents and businesses can now eagerly sign up for WOW!'s all-fiber services that come with simplified pricing, marking a significant milestone in the company's expansion efforts within the state. Enhanced Connectivity for Communities WOW! Internet, TV & Phone (NYSE: WOW), renowned for its reliable broadband services, has...

Continue Reading